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A B S T R A C T
Background
Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells. These are rigid and may block blood
vessels leading to acute painful crises and other complications. Recent research has focused on therapies to rehydrate the sickled cells
by reducing the loss of water and ions from them. Little is known about the effectiveness and safety of such drugs. This is an updated
version of a previously published review.
Objectives
To assess the relative risks and benefits of drugs to rehydrate sickled red blood cells.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group’s Haemoglobinopathies Trials Register.We also searched online
trials registries for any ongoing trials (01 July 2018).
Last search of the Group’s Haemoglobinopathies Trials Register: 08 October 2018.
Selection criteria
Randomized or quasi-randomized controlled trials of drugs to rehydrate sickled red blood cells compared to placebo or an alternative
treatment.
Data collection and analysis
Both authors independently selected studies for inclusion, assessed study quality and extracted data.
Main results
Of the 51 studies identified, three met the inclusion criteria, including 524 people with sickle cell disease aged between 12 and 65 years
of age. One study tested the effectiveness of zinc sulphate as compared to placebo and the remaining two assessed senicapoc versus
placebo. No deaths were seen in any of the studies (low-quality evidence). The zinc sulphate study showed a significant reduction in
painful crises (in a total of 145 participants) over one and a half years, mean difference -2.83 (95% confidence interval -3.51 to -2.15)
(moderate-quality evidence). However, analysis was restricted due to limited statistical data. Changes to red blood cell parameters and
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blood counts were inconsistent (very low-quality evidence). No serious adverse events were noted in the study. The Phase II dose-
finding study of senicapoc (a Gardos channel blocker) compared to placebo showed that the high dose senicapoc showed significant
improvement in change in hemoglobin level, the number and proportion of dense red blood cells, red blood cell count and indices
and hematocrit value (very low-quality evidence). The results with low-dose senicapoc were similar to the high-dose senicapoc group
but of lesser magnitude. There was no difference in the frequency of painful crises between the three groups (low-quality evidence). A
subsequent Phase III study of senicapoc was terminated early since there was no difference observed between the treatment and control
groups in the primary end point of painful crises.
Authors’ conclusions
While the results of zinc for reducing sickle-related crises are encouraging, larger and longer-term multicenter studies are needed to
evaluate the effectiveness of this therapy for people with sickle cell disease.
While the Phase II and the prematurely terminated phase III studies of senicapoc showed that the drug improved red blood cell survival
(depending on dose), this did not lead to fewer painful crises.
Given this is no longer an active area of research, this review will no longer be regularly updated.
P L A I N L A N G U A G E S U M M A R Y
Drugs that aim to reduce the loss of water from red blood cells in people with sickle cell disease
Review question
We reviewed the evidence to assess the relative risks and benefits of drugs to rehydrate sickled red blood cells.
Background
Sickle cell disease is an inherited condition that causes red blood cells to become sickle shaped when they lose water. This leads to a
high risk of the blood vessels becoming blocked. Such blockages can cause pain, stroke and damage to organs. Recent therapies aim to
stop the cells becoming sickle shaped by preventing them losing water.
Search date
The evidence is current to: 08 October 2018.
Study characteristics
The review included three studies with 524 people with sickle cell disease aged between 12 and 65 years of age. The intervention in one
study was zinc sulphate and in two studies was senicapoc. Each study was compared to a placebo group (a substance which contains
no medication). For each study people were selected for one treatment or the other randomly. The studies lasted from three months to
18 months.
Key results
The study with zinc sulphate showed that this drug may be able to reduce the number of sickle cell crises without causing toxic effects
(low-quality evidence). There were 145 participants in this study and results showed a significant reduction in the total number of
serious sickle-related crises over one and a half years, mean difference -2.83 (95% confidence interval -3.51 to -2.15) (moderate-quality
evidence). However, our analysis was limited since not all data were reported. Changes to red blood cell measurements and blood counts
were not consistent (very low-quality evidence). No serious adverse events were noted in the study. The two studies with senicapoc
demonstrated that this drug increases the red blood survival and has a role in preventing red blood cell dehydration in people with
sickle cell disease (very low-quality evidence). The higher dose of the drug was more effective compared to the lower dose. But these
changes in the red blood cells did not translate into positive clinical outcomes in terms of reduction in the number of sickle cell crises
(low-quality evidence). Senicapoc had a favourable safety profile. More longer-term research is needed on these drugs and others that
might prevent water loss in red blood cells.
Given this is no longer an active area of research, this review will no longer be regularly updated.
Quality of the evidence
The quality of the evidence was mixed across outcomes.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Drugs to prevent red blood cell dehydration compared with placebo for sickle cell disease
Patient or population: adults and children with sickle cell disease
Settings: outpat ients
Intervention: drugs to prevent red blood cell dehydrat ion (ant i-sickling treatment)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Anti- sickling drug
Number of deaths
Follow-up: 12 weeks to
18 months
No deaths were seen in any of the studies in either group. 524
(3)
⊕⊕©©
low1,2
Number of sickle pain
crises
Follow-up: 12 weeks to
18 months
There was no signif icant dif f erence in the rate of the sickle cell painful
crises between the senicapoc and placebo groups in either study (Ataga
2008; Ataga 2011).
There were 1.40 and 3.38 painful crises per part icipant in the zinc and
control groups respect ively (Gupta 1995).
524
(3)
⊕⊕©©
low1,2
No data were available
to enter into the analy-
sis for any of the three
studies
In the Gupta study, SDs
could not be calculated
f rom the data provided
in the publicat ion (Gupta
1995).
The 2011 Ataga study
was term inated early
and so there were few
part icipants that com-
pleted treatment and du-
rat ion of treatment var-
ied (Ataga 2011).
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Number of serious
complicat ions of sickle
cell disease: mean
number of crises
Follow-up: 18 months
MD between the groups for the number of other sickle-related compli-
cat ions, MD -2.83 (95% CI -3.51 to -2.15) in favour of the ant i-sickling
treatment (Gupta 1995).
145
(1)
⊕⊕⊕©
moderate3
Test for overall ef fect: Z
= 8.20 (P < 0.00001).
Red blood cell dehydra-
t ion
Follow-up: 12 weeks to
18 months
High and low doses of senicapoc resulted in a signif icant decrease
in the percentage of dense red blood cells compared to the placebo
(Ataga 2008). There was a signif icant decrease in the MCV and MCH in
the high-dose senicapoc group compared to the placebo. The low-dose
senicapoc caused a signif icant reduct ion in the MCH but not MCV when
compared to the placebo. There was no signif icant dif f erence in MCHC
between the 2 intervent ion arms and the placebo arm
The Gupta paper reported signif icant improvements in laboratory pa-
rameters of red blood cell dehydrat ion (hemoglobin, ret iculocyte count,
serum bilirubin and serum zinc level) in the intervent ion group (Gupta
1995).
524
(3)
⊕©©©
very low4,5
There were no data avail-
able to enter into anal-
ysis and we have pre-
sented the results narra-
t ively
Quality of lif e: Days of
work lost per crisis
Follow-up: 18 months
MD between the groups for the number of days of work lost per crisis,
MD -1.50 (95%CI -2.24 to -0.76) in favour of the ant i-sickling treatment
(Gupta 1995).
145
(1)
⊕⊕⊕©
moderate3
The study also reported
mean number of days in
hospital per crisis to be
slight ly higher in the in-
tervent ion group but this
was not signif icant, MD
0.40 (95% CI -0.26 to 1.
06)
Number of other sickle-
related events:
Follow-up: 12 weeks to
18 months
One study showed no dif ference in other sickle-related events between
ant i-sickling treatment and placebo (Ataga 2008).
90
(1)
⊕⊕©©
low1,2
In the remaining stud-
ies, other events were
events in the ant i-sick-
ling treatment
groups were staphylo-
coccal sepsis (n = 1), uri-
nary tract infect ion (n =
1), muscle strain (n = 1)
and one case of bronchi-
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t is in the placebo group
There were less
episodes of infect ion re-
ported in the interven-
t ion group compared to
the control group (Gupta
1995).
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentrat ion; MCV: mean corpuscular volume; MD: mean dif ference; RR:
risk rat io; SD: standard deviat ion.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. Downgraded once due to low event rates causing imprecision.
2. Downgraded once due to risk of bias f rom one study being term inated early and part icipants receiving treatment for
dif f erent durat ions.
3. Downgraded once due to risk of bias within the single study. Lit t le information was given regarding baseline characterist ics,
making it dif f icult to ascertain if the groups were suf f icient ly sim ilar at the start of the study.
4. Downgraded twice due to risk of bias f rom one study being term inated early and part icipants receiving treatments for
dif f erent durat ions and one study giving lit t le information on baseline characterist ics and numbers in each arm.
5. Downgraded once due to imprecision as no data were available to analyse and only narrat ive results could be included.
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B A C K G R O U N D
Description of the condition
Sickle cell disease is caused by the inheritance from both parents
of a mutation in the beta-globin gene. The different types of the
disease (e.g. SS, SC, SβThal) are caused by inheritance of different
altered beta-globin genes, and this can be diagnosed with blood
tests or genetic testing. It is so named because the red blood cells
(erythrocytes) become distorted into unusual shapes when they
give up the oxygen they carry, due to polymerisation of the ab-
normal hemoglobin within. This is accelerated by a cycle of red
blood cell dehydration, which increases intracellular concentra-
tion of the sickle hemoglobin and hence polymerisation. One of
the distinguishing features of sickle cell anemia is the presence of
these dense, dehydrated red blood cells, which are easily destroyed
and can mesh together to block blood vessels (vaso-occlusion).
The disease is characterised by episodes of anemia, vaso-occlusive
crises and organ damage, with symptoms which are unpredictable
and differ between individuals (Serjeant 1992). It is most preva-
lent in populations originating from sub-Saharan Africa and parts
of India; although population movement has made it a world-
wide problem, with approximately 60,000 African-American and
10,000 British people with the disease (Davies 1997; Hickman
1999). Clinical management centers around prophylaxis against
infection, pain relief, hydration and periodic blood transfusion
in many people to reduce the concentration of sickle cells in the
blood stream. However, most treatment is symptomatic and, as
a result, despite vastly improving care services, many people with
the disease still die in childhood due to sudden bouts of infec-
tion, stroke, acute chest syndrome or splenic sequestration (Leikin
1989). Clearly preventative measures would be preferable.
How the intervention might work
In an attempt to prevent the increased concentration of sickle
hemoglobin (which causes polymerisation and deformation of the
red blood cell), recent research has begun to target the physiologi-
cal process leading to dehydration of the erythrocyte for therapeu-
tic potential. Red blood cells are thought to undergo dehydration
via two kinetically distinct pathways, a “fast track” process in retic-
ulocytes (immature red blood cells), and a slow process involv-
ing mature erythrocytes. Dehydration via either pathway is due to
the water loss accompanying primary loss from the cell of potas-
sium and chloride ions. The major routes involved in sickle cell
dehydration are the calcium-activated potassium channel (Gardos
channel) operating in parallel with the conductive chloride path-
way and the electroneutral potassium-chloride co-transporter(s)
(Brugnara 1995). Potential therapeutic approaches involve the use
of drugs that reduce sickle cell dehydration via a block of these
mechanisms.
The first route, and perhaps the most promising for therapy, is
the Gardos channel. Upon deoxygenation of the sickle cell, potas-
sium and water loss are induced as free intracellular calcium lev-
els rise, possibly due to increased membrane permeability for cal-
cium. The Gardos channel may also be positively modulated by
vaso-active molecules such as endothelins (Rivera 2000). Studies
both in a mouse model for sickle cell disease (SAD mouse) and in
humans have shown that this channel can be selectively inhibited
by a group of drugs known as the imidazole antimycotics, includ-
ing the anti-fungal agent clotrimazole (Brugnara 1993; Brugnara
1996; de Franceschi 1994) and a related compound Senicapoc
(ICA-17043) (Stocker 2000). Blocking of the Gardos channel re-
sulted in increased potassium content and improved hydration
of erythrocytes. Senicapoc (bis(4-fluorophenyl)phenyl acetamide)
is a selective and potent blocker of the Gardos channel (Stocker
2003). Dimethyl adipimate may also have an anti-sickling role via
the Gardos channel (Gibson 2000).
The role of the chloride conductance or exchange system in sickle
cell dehydration has also been recently explored. In vitro, loss of
potassium from deoxygenated human sickle cells could be limited
by the reversible anion conductance inhibitor NS1652 (Bennekou
2000). Further, the related compound,NS3623 (Bennekou2001),
which has a greater half-life in vivo, improved hydration in the
SAD mouse.
Potassium-chloride co-transport occurs via a different membrane
protein, which is activated by acidity within the cell allowing loss
of potassium and water. This is seen almost exclusively in reticu-
locytes. No drugs have been found to be useful in inhibiting the
transporter, but it has been shown that divalent cations, such as
magnesium ions (Brugnara 1987), can block the pathway, again
protecting against dehydration. Magnesium preparations are cur-
rently marketed for treatment of constipation, boils, recurrence
of seizures in eclampsia, renal failure and are recommended for
emergency treatment of serious arrhythmias. Magnesium pidolate
has been investigated in combination with hydroxyurea in a Phase
I trial (Hankins 2008).
Other strategies have also been suggested for reducing sickle red
blood cell dehydration. These include a transmembrane sodium-
potassium pump mechanism which is partly responsible for in-
creased ion permeability on deoxygenation. While this is thought
to be a minor contributor to dehydration, dipyridamole has been
shown to be a selective inhibitor of passive ion transfer and there is
rationale, including the known effects on platelet and endothelial
cell function, for testing its efficacy in sickle cell disease. Oxidative
damage to the cell membrane, which can occur in sickle cell dis-
ease due to abnormal iron deposits, increases loss of potassium and
water contributing to red blood cell dehydration (Brugnara 1995).
Oral iron chelators may help in this case, and antioxidants could
also be useful (Gibson 1998). Nitric oxide, an endogenous com-
pound which is thought to be an important regulator of smooth
muscle tone and vasodilatation, is reduced in people with sickle
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cell disease (Qureshi 2000). Preliminary studies in SADmice have
shown that it can reduce red blood cell dehydration (Adrie 2000),
and oral supplementation with arginine, an amino acid which re-
leases nitric oxide, (5% by weight) also induces a decrease in red
blood cell density (Romero 2000), via Gardos channel activity
(Romero 2002). Hydroxyurea, an anti-cancer compound proven
to reduce sickle-related events (Charache 1995; Jones 2001), im-
proves the hydration status of sickle red blood cells (Ballas 1989),
although it is not clear whether this is a direct effect, or a conse-
quence of increased levels of fetal hemoglobin (HbF).
In Brazil a local plant, Pfaffia paniculata, has been anecdotally
reported to ameliorate clinical symptoms of sickle cell disease. The
plant possibly contains a naturally occurring compound, which
acts as a sodium ionophore. In vitro studies have shown increased
erythrocyte deformability and sodium content of sickle red blood
cells when treated with it, thus potentially rehydrating sickle cells
(Ballas 2000).
Piracetam (2-oxo-1-pyrrolidine acetamide), a derivative of the
neurotransmitter gamma-aminobutyric acid (GABA), works pri-
marily in neurotransmission, but appears to have a beneficial effect
on red blood cell rheology and thus able to reduce vaso-occlusive
crises in people with sickle cell disease. The exact mechanism of
this remains unclear. It does not appear to inhibit theGardos chan-
nel as previously reported (Gini 1987; Stone 1988; Stuart 1990;
Stuart 1992). The use of piracetam for reducing the incidence of
painful sickle cell disease crises is the subject of another Cochrane
Review (Al Hajeri 2007).
Why it is important to do this review
All of these potential therapies look promising for reducing dehy-
dration of red blood cells, and therefore ameliorating the symp-
toms of sickle cell disease. This review aims to bring together clin-
ical trials in this area to establish the clinical value of this pharma-
ceutical approach.
This is an update of previously published versions of the review
(Nagalla 2010; Nagalla 2012; Riddington 2002; Singh 2007).
O B J E C T I V E S
To determine whether pharmaceutical therapies designed to pre-
vent red blood cell dehydration in sickle cell disease:
1. reduce mortality;
2. reduce sickle cell vaso-occlusive crises including episodes of
pain and stroke;
3. reduce other complications associated with sickle cell
disease, e.g. acute chest syndrome, infection, anemia, splenic
sequestration, organ damage;
4. are associated with unacceptable adverse events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized or quasi-randomized trials. Trials in which quasi-
randomized methods, such as alternation, are used were included
if there was sufficient evidence that the treatment and control
groups were similar at baseline.
Types of participants
People with known sickle cell disease (SS, SC, Sβ+ and Sβ0,
proven by electrophoresis and sickle solubility test, with family
studies or DNA tests as appropriate) of all ages and both sexes, in
any setting.
Types of interventions
Pharmaceutical therapies designed to reduce red blood cell dehy-
dration to prevent vaso-occlusive events in sickle cell disease com-
pared to comparator interventions. Studies which included anti-
sickling drugs for which the exact mechanism of action is not
known were considered if there was some evidence that they act
via the red blood cell membrane to prevent sickling. Piracetam
was excluded since there is insufficient evidence that it acts pri-
marily via the red blood cell membrane to improve red blood cell
rheology. Hydroxyurea was excluded as the primary mechanism
for this drug is through increasing foetal hemoglobin. Studies in
which the intervention was given only to treat an existing sickle-
related event were excluded.
Types of outcome measures
While the interventions should, by definition, decrease dense sick-
led cells by reducing erythrocyte dehydration, such biochemical
parameters were examined separately from clinical outcomes, to
determine the effectiveness of the interventions in clinical prac-
tice. However, the hematological outcomes may also provide an
indication of the efficacy, and potential effectiveness, of treatment,
so these were also analyzed.
Primary outcomes
1. Number of deaths
2. Number of sickle pain crises (requirement for opiate
treatment or self-reported patient scales)
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3. Number of serious complications of sickle cell disease
including stroke, acute chest syndrome and acute splenic
sequestration
Secondary outcomes
1. Red blood cell dehydration (proportion of dense cells,
mean corpuscular hemoglobin concentration (MCHC), mean
corpuscular volume (MCV))
2. Full blood count including hemoglobin, white blood cell
and platelet counts, sickle cell hemoglobin (HbS) and foetal
hemoglobin (HbF) level
3. Quality of life: days off work or school, hospitalisations,
mobility, etc.
4. Number of other sickle-related events, including priapism,
leg ulceration
Other outcomes
1. Any reported adverse effects or toxicity of drugs were
recorded
Search methods for identification of studies
There were no restrictions regarding language or publication sta-
tus.
Electronic searches
Relevant studies were identified from the Cystic Fibrosis & Ge-
netic Disorders Review Group’s Haemoglobinopathies Trials Reg-
ister using the terms: (sickle cell OR (haemoglobinopathies AND
general)) [kw]AND(dehydration [kw,ti,ab]OR (anti-sicklingOR
crisis) [kw])
The Haemoglobinopathies Trials Register is compiled from elec-
tronic searches of theCochraneCentral Register of ControlledTri-
als (CENTRAL) (updated each new issue of theCochrane Library)
and weekly searches of MEDLINE. Unpublished work is iden-
tified by searching the abstract books of five major conferences:
the EuropeanHaematology Association conference; the American
Society of Hematology conference; the British Society for Haema-
tology Annual Scientific Meeting; the Caribbean Public Health
AgencyAnnual ScientificMeeting (formerly theCaribbeanHealth
Research Council Meeting); and the National Sickle Cell Disease
Program Annual Meeting. For full details of all searching activities
for the register, please see the relevant section of the Cochrane
Cystic Fibrosis and Genetic Disorders Group’s website.
Date of the most recent search of the Group’s
Haemoglobinopathies Trials Register: 08 October 2018.
We also searched theWorldHealthOrganization (WHO) Interna-
tional Clinical Trials Registry Platform ( ICTRP) ( apps.who.int/
trialsearch/) and ClinicalTrials.gov ( www.ClinicalTrials.gov) for
any ongoing trials (01 July 2018) (Appendix 1).
Searching other resources
The bibliographic references of all retrieved literature were re-
viewed for additional reports of studies.
Data collection and analysis
Selection of studies
Two authors independently applied the inclusion criteria in order
to select studies for inclusion in the review. If disagreement arose
on the suitability of a study for inclusion in the review, the authors
reached consensus by discussion.
Data extraction and management
Two authors independently extracted the data. Each author, using
standard data acquisition forms, independently extracted data. If
disagreement arose on the study quality, the authors reached a
consensus by discussion.
We planned to collect data at monthly time-frames. However, if
data were reported at other time periods we planned to consider
examining these as well.
Assessment of risk of bias in included studies
Two authors assessed the risk of bias of each study. In particular,
authors examined details of the randomization method, allocation
concealment, whether the study was blinded, whether intention-
to-treat analyses were possible from the available data and if the
number of participants lost to follow up or subsequently excluded
from the study was recorded.
Measures of treatment effect
We recorded dichotomous outcomes e.g. life or death, as present
or absent, whilst recording continuous data such as organ func-
tion tests as either mean change from baseline for each group or
mean post treatment values and standard deviation (SD) for each
group. We aimed to calculate a pooled estimate of the treatment
effect for each outcome across studies, (for binary outcomes the
odds of an outcome among treatment allocated participants to the
corresponding odds among controls).
Unit of analysis issues
Cross-over trials will only be included in future versions of this
review if we consider there to be a sufficient washout period be-
tween the treatment arms. We will analyze any data from such tri-
als according to methods described by Elbourne (Elbourne 2002).
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Dealing with missing data
We sought full reports from authors where studies have been pub-
lished in abstract form, presented at meetings or reported to the
co-authors. Where information was missing or unclear, we con-
tacted the primary investigator.
In order to allow an intention-to-treat analysis, we grouped data
by allocated treatment groups, irrespective of later exclusion (re-
gardless of cause) or loss to follow up.
Assessment of heterogeneity
We will test for heterogeneity between studies using a standard
chi-squared test and I² statistic (Higgins 2003). We will use the
following ranges to describe heterogeneity:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
Comprehensive searches were done by both the authors to mini-
mize publication and reporting biases. We compared the ’Meth-
ods’ section of the full published paper to the ’Results’ section to
ensure that all outcomes which were measured, were reported.
Data synthesis
Wehave used fixed-effect analysis with the data we have presented.
If there is a high or moderate degree of heterogeneity between
studies included in any future updates, we will consider using a
random-effects analysis.
Subgroup analysis and investigation of heterogeneity
If we find heterogeneity between studies, examination of sub-
groups, such as age of participants, type of sickle cell disease or
ethnicity, may help to explain the reasons for this.
For future updates, where appropriate, we plan to perform sub-
group analysis of different drugs or combinations of drugs to ex-
amine their relative risks and benefits.
Sensitivity analysis
If we include a sufficient number of studies where quasi-random-
ization methods are used, we will analyze this group separately.
Summary of findings tables
In a post hoc change, we have presented a summary of findings
table (Summary of findings table 1).
All seven outcomes were included:
1. Number of deaths
2. Number of sickle pain crises (requirement for opiate
treatment or self-reported patient scales)
3. Number of serious complications of sickle cell disease
including stroke, acute chest syndrome and acute splenic
sequestration
4. Red blood cell dehydration (proportion of dense cells,
mean corpuscular hemoglobin concentration (MCHC), mean
corpuscular volume (MCV))
5. Full blood count including hemoglobin, white blood cell
and platelet counts, sickle cell hemoglobin (HbS) and foetal
hemoglobin (HbF) level
6. Quality of life: days off work or school, hospitalisations,
mobility, etc.
7. Number of other sickle-related events, including priapism,
leg ulceration
We determined the quality of the evidence using the GRADE
approach; and downgraded evidence in the presence of a high
risk of bias in at least one study, indirectness of the evidence,
unexplained heterogeneity or inconsistency, imprecision of results,
high probability of publication bias. We downgraded the evidence
by one level if we considered the limitation to be serious and by
two levels if very serious.
R E S U L T S
Description of studies
Results of the search
We identified 232 references and discarded 163 references as they
were not relevant to the review. We further assessed 69 references
(to 51 studies) and included three studies within the review (Ataga
2008; Ataga 2011; Gupta 1995) and excluded the remaining 48
studies.
Included studies
Trial design
All three studies were described as double-blind, randomized
placebo-controlled studies (Ataga 2008; Ataga 2011; Gupta
1995). The Phase II Ataga study was a dose-finding study which
compared a 10 mg dose of senicapoc to a 6 mg dose of senicapoc
or to placebo. The trial was multicenter (19medical centers) in the
USA (Ataga 2008). The study treated participants for 12 weeks
(Ataga 2008).The more recent senicapoc trial was a Phase III trial
was conducted across 75 centers in 6 countries (Ataga 2011). The
participants were randomized to senicapoc (20 mg twice daily as
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a loading dose for 4 days followed by 10 mg daily) or placebo in a
1:1 fashion. The treatment phase consisted of 52 weeks followed
by a follow-up period of 8 weeks (Ataga 2011). The Gupta trial
compared oral zinc (220 mg three times a day) to placebo. The
trial was from a single center in India (Gupta 1995). The Gupta
study lasted for one and a half years; participants were seen weekly
but data were analysed at the end of the follow-up period (Gupta
1995).
Participants
There were 524 participants with sickle cell disease included in the
review. The Phase II senicapoc study randomized 90 participants
aged between 18 to 60 years (Ataga 2008). The Phase III senicapoc
study randomized 297 participants between the ages of 16 and
65 years, but only the 289 participants in the modified intent-
to-treat group (participants who received at least one dose of the
drug) were included in this review (Ataga 2011). In the remaining
study, Gupta randomized 145 participants aged between 12 to 27
years (Gupta 1995).
In the Phase II senicapoc study, participants had at least one
episode of sickle cell-related painful crisis four weeks prior to the
study screening and participants taking hydroxyurea had to be on
a stable dose of the drug for at least three months prior to their
enrolment in the study (Ataga 2008). In the Phase III senicapoc
study, participants had at least two episodes of painful crisis within
the preceding 12 months that required medical attention (Ataga
2011). Participants on hydroxyurea in preceding 12 months were
required to be on a stable dose of the drug prior to inclusion in
the study (Ataga 2011). Gupta excluded participants under five
years of age or those who had a history of chronic persistent infec-
tion, evidence of organ failure, exposure to extreme temperatures
or were taking other medication (Gupta 1995).
In the Phase II senicapoc study, all the participants who received at
least one week of the drug and underwent the initial efficacy anal-
ysis were included in the modified intent-to-treat analysis. Eighty-
eight participants met this criteria and only two discontinued the
study before the initial efficacy analysis (Ataga 2008). In the Phase
III senicapoc study 289 participants from the initial group of 297
were included in the modified intent-to-treat analysis based on
participants who received at least one dose of the drug (Ataga
2011). However, in the Gupta study, 15 participants out of the
original 145 subsequently dropped out or were lost to follow-up,
and these were not included in the analysis (Gupta 1995).
Interventions
The Phase II senicapoc study compared three groups: high-dose
senicapoc (single 150 mg loading dose followed by 10 mg daily
maintenance dose); or low-dose senicapoc (single 100 mg loading
dose followed by 6 mg daily maintenance dose); or placebo (Ataga
2008). The high-dose senicapoc group had 31 participants, the
low-dose senicapoc and placebo groups had 29 and 30 participants
assigned respectively. The Phase III senicapoc study stratified par-
ticipants based on concomitant hydroxyurea therapy. In each of
these groups participants were randomized to receive senicapoc
(loading dose of 20mg twice daily for four days followed by 10mg
daily) or placebo in a 1:1 fashion. Out of the 289 participants in
the modified intent-to treat analysis, there were 163 participants
in the hydroxyurea group and 126 in the non-hydroxyurea group.
The hydroxyurea group had 84 participants receiving senicapoc
and 79 participants on placebo. The non-hydroxyurea group had
61 senicapoc participants and 65 in the placebo group (Ataga
2011). The third study randomized participants to receive either
zinc sulphate (220 mg three times a day orally) or an identical
placebo (Gupta 1995).
Outcomes measured
The Ataga Phase II study reported the effect of senicapoc on
hemoglobin levels, red blood cell (RBC) indices, markers of
hemolysis and painful crises. The primary end point of the study
was the change in hemoglobin level with the secondary end points
being changes in the number and proportion on the dense red
blood cells (RBCs) and reticulocytes, lactate dehydrogenase, indi-
rect bilirubin, RBC count, RBC indices, hematocrit and frequency
of painful crises (Ataga 2008). The primary end point in the Ataga
Phase III was the frequency of sickle cell pain crises. TIme to the
first, second and third acute painful crises was a secondary end
point of the study (Ataga 2011). The effect of the drug on mark-
ers of hemolysis, hemoglobin, hematocrit, reticulocyte count, red
blood cell count and dense erythrocytes were also measured. The
Gupta study measured the number of sickle-related crises, and the
number of days in hospital and working (or school) days lost for
each crisis (Gupta 1995).
Excluded studies
Forty-eight studies were excluded. Reasons for exclusions were a
lack of evidence that they were acting primarily on red blood cell
dehydration pathways, or they were being used to treat a sickle-
related crisis, rather than preventing it, or the study was not ran-
domized (see Characteristics of excluded studies table). Studies on
piracetam were excluded since there is insufficient evidence that
this drug acts primarily via the red blood cellmembrane to improve
red blood cell rheology (Alvim 2005; Piracetam Study 1998).
Risk of bias in included studies
Allocation
All three studies were judged to have a low risk of bias for the
generation of the allocation sequence (Ataga 2008; Ataga 2011;
Gupta 1995). In both of the senicapoc studies an integrated voice
10Drugs for preventing red blood cell dehydration in people with sickle cell disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
response system was used in the centralized randomization pro-
tocol (Ataga 2008; Ataga 2011). In the zinc study, New Castle
software was used to generate randomization (Gupta 1995).
Both the senicapoc studies and the zinc study did not report on
allocation concealment and so all studies were judged to have an
unclear risk of bias for this criteria (Ataga 2008; Ataga 2011;Gupta
1995).
Blinding
Both the participants and treating physicians were blinded in all
three studies and so were judged to have a low risk of bias (Ataga
2008; Ataga 2011; Gupta 1995). Additionally, Ataga reported that
the review committee were also blinded (Ataga 2008).
Incomplete outcome data
In the senicapoc Phase II study, a modified intent-to-treat popula-
tion was used in the efficacy analysis (Ataga 2008). Two out of the
the 90 participants dropped out prior to the initial assessment and
so 88 participants were included as a part of the modified intent-
to-treat population. The safety analysis included all the 90 partic-
ipants. A total of 10 participants did not complete the study; full
reasons for this were given in the published paper and we therefore
judged there to be a low risk of bias due to incomplete outcome
data (Ataga 2008).
The Phase III senicapoc study was terminated early due to a lack of
efficacy as determined by the unblinded Data Monitoring Com-
mittee (Ataga 2011). The reasons for the Committee’s decision
were based on the fact that there was no significant improvement
in the rate of sickle cell painful crises in participants treated with
senicapoc compared to those on placebo (P = 0.38 versus P =
0.31 respectively) despite improvements in anemia and hemoly-
sis. Moreover, comparisons of the times to first, second and third
crises between the senicapoc and placebo groups were not signifi-
cantly different. The authors suggest that the increase in Hb level
caused an increase in blood viscosity and offset the potential ben-
efits of senicapoc with regards to painful crises. Furthermore, due
to the early termination of the study, the duration that the drug
was administered was different in the participants who stopped
treatment early. Given these facts, we have not entered any data
from this trial into the data tables and results are reported narra-
tively.
In the zinc study, a power calculation, which assumed 40% control
event rate and 20% response, found that 130 participants were
needed. Fifteen, of the 145 participants recruited, dropped out
or were lost to follow-up, and these are not accounted for in the
study publication (Gupta 1995). We therefore judge there to be
an unclear risk of bias from reported outcome data for this study.
Selective reporting
In both the senicapoc studies and the zinc study, all outcomes
stated in ’Methods’ section were reported in the ’Results’ section
of the papers; therefore there is a low risk of bias for selective
reporting for all studies (Ataga 2008; Ataga 2011; Gupta 1995).
Other potential sources of bias
The participants in the Phase II senicapoc study were evenly
matched in terms of their baseline characteristics between the three
study arms (Ataga 2008) and this was also true for the Phase III
senicapoc study (Ataga 2011). There was no significant difference
in the mean age, sex and the hospitalizations in the year prior to
the enrolment in the study. We therefore judged both studies to
have a low risk of bias for this domain.
The zinc study gave little information regarding baseline charac-
teristics, including disease severity and medical history of partici-
pants, making it difficult to ascertain if the groups were sufficiently
similar at the start of the study (Gupta 1995). Thus currently we
judge there to be an unclear risk of bias for this study.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
1. Number of deaths
No treatment related deaths were reported in the included studies
(low-quality evidence) (Analysis 1.1) (Ataga 2008; Ataga 2011;
Gupta 1995).
2. Number of pain crises
Nodata were available to enter into the analysis for any of the three
studies (low-quality evidence) (Gupta 1995; Ataga 2008; Ataga
2011).
In the senicapoc Phase II study there were a total of 15 sickle
cell crises, with the events being distributed equally between the
placebo and the two intervention arms (five in each) (Ataga 2008).
So both the lower (6 mg) and higher doses (10 mg) of senicapoc
did not help in the reduction of painful crises compared to placebo.
The Phase III senicapoc studywas terminated prematurely as it was
unlikely to meet the primary endpoint (Ataga 2011). There was
no significant difference in the rate of the sickle cell painful crises
between the senicapoc and placebo groups (0.38 versus 0.31, P =
0.054). There was no difference in the painful crises rate between
the two treatment arms in the hydroxyurea group (0.39 versus
0.33, P = 0.483) but the rate of painful crises was significantly
higher in the senicapoc group compared to the placebo group in
participants not on hydroxyurea (0.37 versus 0.29, P = 0.037)
(Ataga 2011). The study included pain-only crises, acute chest
syndrome, hepatic sequestration, priapism and stroke under the
primary end point of sickle cell-related pain crises. Given that the
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study was terminated prematurely, there are very few participants
who completed the treatment. The duration of the drug regimen
was different in the participants who stopped treatment. Therefore
we have not included any data from this trial in the data analysis
table.
In the zinc study there were 91 vaso-occlusive crises in the in-
tervention group, compared to 220 in the control group (Gupta
1995). This amounts to, on average, 1.40 and 3.38 painful crises
per participant in intervention and control groups respectively.
Standard deviations cannot be calculated from the data provided
in the publication, so we are attempting to contact the authors,
and hope to provide this information in a future update.
3. Number of other serious sickle-related complications
In the Phase II senicapoc study, there were two episodes of pneu-
monia and one episode of bronchitis in the placebo group (Ataga
2008). There was one episode of pneumonia in each of the inter-
vention arms. There was a single episode of acute chest syndrome
in the study and it occurred in the 6 mg (low-dose) senicapoc arm.
There was one episode of aseptic necrosis of the bone in the low-
dose senicapoc arm and one episode of deep venous thrombosis in
the high-dose senicapoc arm. Furthermore, there was one episode
of staphylococcal sepsis in the low-dose senicapoc group and one
urinary tract infection in the high-dose senicapoc group. The only
case of deep vein thrombosis was reported in the high-dose seni-
capoc group (Ataga 2008).
The Phase III senicapoc study included pain-only crises, acute
chest syndrome, hepatic sequestration, priapism and stroke under
the primary end point of sickle cell-related pain crises (Ataga
2011).
In the zinc study, altogether there were 160 episodes of sickle-
related crises in the intervention group, and 344 in the control
group (Gupta 1995). Of these, vaso-occlusive crises accounted for
59% in the intervention group and 64% in the control group,
mixed crises for 24% and 20% in the intervention and control
groups respectively, 9% and 12% were hemolytic, 1% in each
group sequestration and 1% in each group had aplastic crises. The
mean number of all sickle-related crises in the intervention group
was 2.46 (SD 1.04), compared to 5.29 (SD 2.58), in the control
group. The MD between groups was -2.83 (95% CI -3.51 to -
2.15), showing a statistically significant reduction in the partici-
pants treated with zinc (moderate-quality evidence) (Analysis 1.2)
(Gupta 1995).
Secondary outcomes
1. Red blood cell dehydration
All three studies presented information on this outcome (very low-
quality evidence) (Gupta 1995; Ataga 2008; Ataga 2011).
Both the high and low doses of senicapoc resulted in a significant
decrease in the percentage of dense red blood cells compared to
the placebo (Ataga 2008). The magnitude of decrease was higher
with the 10 mg senicapoc compared to the 6 mg senicapoc. There
was a significant decrease in the MCV and mean corpuscular
hemoglobin (MCH) in the high-dose senicapoc group compared
to the placebo. The low-dose senicapoc caused a significant reduc-
tion in the MCH but not MCV when compared to the placebo.
There was no significant difference in MCHC between the two
intervention arms and the placebo arm. The biochemical mark-
ers of hemolysis like lactate dehydrogenase and indirect bilirubin
were significantly lower in the senicapoc groups compared to the
placebo group. The magnitude of the change was dependent on
the dose of senicapoc.
The findings seen in the Phase II senicapoc study were confirmed
in the Phase III study where senicapoc was compared to a placebo
(Ataga 2011).
The Gupta paper reported significant improvements in laboratory
parameters of red blood cell dehydration (hemoglobin, reticulo-
cyte count, serum bilirubin and serum zinc level) in the interven-
tion group (Gupta 1995).
2. Full blood count
The senicapoc study demonstrated an increase in the hemoglobin
level by 0.68 gm/dL in the high-dose senicapoc group compared to
the 0.01 gm/dL increase in the placebo group (P < 0.001) (Ataga
2008). There was no significant change in the hemoglobin level
when 6 mg of senicapoc was compared to the placebo. There was
significant increase in the RBC count with senicapoc compared to
the placebo in a dose-dependent manner.
Both the high and low doses of senicapoc resulted in a significant
decrease in the percentage and absolute number of reticulocytes
(Ataga 2008).
The above findings were confirmed in the Phase III senicapoc
study. There was no significant change in the HbF levels (Ataga
2011).
Gupta reported that participants in the intervention group had
a mean hemoglobin level of 7.9 g/dL compared to 6.8 g/dL in
the control group (P < 0.01) (Gupta 1995). Other outcomes were
not reported, and SDs were not given. Again, the authors will be
contacted to clarify this information.
3. Quality of life measures
Thesemeasures were not assessed in the Phase II study of senicapoc
(Ataga 2008).
In the Phase III senicapoc study there was no difference in the
FACIT-Fatigue scores between the two treatment arms irrespective
of the hydroxyurea stratification. Similarly, there was no difference
in the number of participants transfused, the number of transfu-
sions or units per participant. The participants on senicapoc spent
more days in the hospital compared to those on placebo (Ataga
2011).
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Gupta reported the mean length of hospital stay per crisis in the
intervention and control groups respectively was 4.3 and 3.9 days,
MD 0.40 (95% CI -0.28 to 1.06), with no significant difference
(Analysis 1.3) (Gupta 1995). Days of work lost per crisis were 3.4
in the zinc group and 4.9 in the control group. Although there is
a significant reduction in the number of work days lost in the zinc
group, MD -1.50 (95% CI -2.24 to -0.76), on average hospital
stay was longer in this group (moderate-quality evidence) (Analysis
1.3).
4. Other sickle-related events
In the Phase II senicapoc study (low-quality evidence), there was
one episode of staphylococcal sepsis in the low-dose senicapoc
group and one urinary tract infection in the high-dose senicapoc
group (Ataga 2008). There was one report of muscle strain in
the high-dose senicapoc group and once case of bronchitis in the
placebo group (Ataga 2008).
In the Phase III senicapoc study there was no significant differ-
ence in other sickle cell-related events (pneumonia, asthma, fever,
catheter-related infections) between the senicapoc and the placebo
groups (Ataga 2011).
In the zinc study, there were 108 episodes of infection reported
in the intervention group compared to 204 in the control group
(Gupta 1995).
5. Adverse drug reactions
In the Phase II senicapoc study three participants discontinued the
study due to adverse events (Ataga 2008). One of the participants
in the low-dose senicapoc group had dyspnoea and weakness and
two in the high-dose senicapoc group had acute chest syndrome
and painful crises. Diarrhea and nausea of mild to moderate in-
tensity were more common in the senicapoc groups compared to
the placebo group.
Nausea and urinary tract infections were significantly higher in the
senicapoc-treated participants compared to placebo in the Phase
III senicapoc study. All other adverse events were similar between
the two treatment groups (Ataga 2011).
The Gupta study states that zinc was well-tolerated with no signif-
icant toxicity throughout the study, although it was unclear which
potential toxic effects were monitored (Gupta 1995).
D I S C U S S I O N
Zinc deficiency in sickle cell disease has been shown in obser-
vational studies to correlate with disease severity (Gupta 1987;
Karayalcin 1974). Laboratory studies have shown that zinc can
improve the sickle cell membrane status and antagonise intracel-
lular calcium, and could therefore affect red blood cell dehydra-
tion (Bennekou 2001). The Gupta study included in this review
showed a significant reduction in the number of sickle-related
events in one and a half years of use in people treated with zinc sul-
phate (moderate-quality evidence) (Gupta 1995). However, lack
of data in the publication makes it difficult to analyse the effect
on other outcomes, on painful crisis frequency in particular (low-
quality evidence). In addition, changes to hematological indices,
which could be used as biomarkers of RBC sickling, were incon-
clusive (very low-quality evidence). Further research is required
to evaluate the effect of zinc on the basic mechanisms of sickle
cell disease. Previous studies using zinc also suggest a benefit for
other problems in sickle cell disease, including leg ulcers (Serjeant
1970), growth (Zemel 2001), infection (Prasad 1999) and andro-
gen deficiency in male participants (Prasad 1981). However, these
studies were not included in the review since they do not consider
prevention of vaso-occlusive crises.
Senicapoc (ICA-17043) is a selective and potent blocker of the
Gardos channel in the RBC (Stocker 2003). The effect of this drug
on the markers of hemolysis and hemoglobin level was evaluated
in a 12-week, Phase II randomized double-blind study in people
with sickle cell disease (Ataga 2008). The findings of this study
suggested an increase in the lifespan of the sickle red blood cells
(very low-quality evidence), but there was no difference in the inci-
dence of painful crises (low-quality evidence). A subsequent Phase
III study was terminated early due to the lack of improvement
in the vaso-occlusive pain crisis in people with sickle cell disease
(Ataga 2011).
A number of other studies did not satisfy the inclusion criteria,
but are still relevant to this review. Cetiedil citrate is believed to act
at the Gardos channel, antagonising the calcium-mediated potas-
sium efflux from RBCs, thus affecting red blood cell hydration
and preventing sickling. In two randomized controlled trials in-
vestigating this treatment of sickle pain crises, both found it to
limit the duration of a pain crisis and reduce the number of sites
of pain compared to placebo (Benjamin 1986; Cabannes 1983).
No studies have tested its use in preventing sickle crises.
Piracetam improves red blood cell rheology; however, the exact
mechanism of this on the red blood cell membrane is unclear.
It was initially believed to inhibit the Gardos channel, but later
studies disproved this theory (Stone 1988; Stuart 1992). It has
been shown in one randomized controlled trial to decrease the
number of pain crises (Piracetam Study 1998) and in another to
have no effect in preventing pain crises (Alvim 2005). For further
information, please see the relevant Cochrane Review (Al Hajeri
2007).
Magnesium is known to inhibit the potassium-chlorine ion pump,
and observational studies have shown benefits in sickle cell disease.
Sodium cromoglicolate can stabilise erythrocyte membranes by
blocking chlorine or calcium channels. In an ex vivo study, two
groups of nine children were given sodium cromoglicolate either
by the nasal route or inhalation (Toppet 2000). The percentage
13Drugs for preventing red blood cell dehydration in people with sickle cell disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of sickled cells in the blood of all children significantly decreased,
regardless of which group they were assigned to. Further studies
are now needed to test the clinical benefit of this agent.
Diltiazem also proved useful in a pilot studywhichmeasured sickle
pain intensity and duration and various hematological parameters
(Rubio 1992). It is a calcium channel blocker and may impact on
red blood cell hydration.
It was been hypothesised that hydroxyurea may increase intrinsic
levels of nitric oxide, and this may affect red blood cell hydration.
Effectiveness of hydroxyurea is considered in a different Cochrane
Review (Jones 2001).
Zinc sulphate appears to be of benefit to people with sickle cell
disease (Gupta 1995).
However, further research in the form of large well-designed ran-
domized controlled trials is required to fully elucidate the true
value in sickle cell disease of drugs which aim to prevent red blood
cell dehydration.
Given this is no longer an active area of research, this review will
no longer be regularly updated.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is low-quality evidence that zinc sulphate is associated with
a reduction in pain crises, and also with reductions in other sickle
cell-related crises. This was despite the treatment not being associ-
ated with an improvement in any of the hematological outcomes.
While these results are encouraging, widespread introduction of
this agent in the management of people with sickle cell disease is
not indicated at present.
Senicapoc clearly improves the red blood cell survival in a dose-
dependent manner (very low-quality evidence). But the improve-
ment in the laboratory measures did not translate into clinical
benefits. There was no reduction in the incidence of sickle cell
crises with the use of senicapoc (low-quality evidence). Therefore,
currently this drug cannot be used in clinical practice for the pre-
vention of vaso-occlusive crises.
Implications for research
More studies are needed to evaluate the effect of zinc sulphate and
of piracetam on the basic mechanisms of sickle cell disease. Fur-
ther multicenter randomized controlled trials of zinc sulphate in
people with sickle cell disease should be conducted. To investigate
whether the findings previously reported are consistent and sus-
tained, these future studies should be larger and longer term than
the one reported in this review. Senicapoc improved red blood cell
survival and decreased hemolysis. Further studies are needed to
ascertain if this drug will be beneficial in some of the other com-
plications of sickle cell disease such as pulmonary hypertension.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ataga 2008
Methods Phase II, randomized, double-blind, placebo-controlled study. There was a screening
phase and a 12-week treatment phase
Participants 90 sickle cell participants were recruited at 19 medical centers in the USA. The partici-
pants were adults aged between 18 and 60 years with at least one episode of sickle cell-
related painful crisis 4 weeks prior to the study screening
Interventions Participants were randomized to either:
1. high-dose senicapoc: a single 150 mg senicapoc loading dose followed by 10 mg daily
maintenance dose;
2. low-dose senicapoc: a single 100 mg senicapoc loading dose followed by 6 mg daily
maintenance dose; or
3. placebo.
Outcomes Efficacy, safety, pharmacokinetic, and pharmacodynamic measures were obtained on day
1 of study, end of week 1 and every 2 weeks until the end of treatment phase
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralized randomization protocol using
an integrated voice response system
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding (performance bias and detection
bias)
Participants
Low risk The participants were blinded.
Blinding (performance bias and detection
bias)
Clinicians
Low risk The treating physicians were blinded.
Blinding (performance bias and detection
bias)
Outcome assessors
Low risk The review committee was blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Modified intent to treat population was
used for analysis. Twoparticipants dropped
out prior to the first efficacy analysis. A to-
tal of ten participants did not complete the
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Ataga 2008 (Continued)
study; full reasons for this were given in the
published paper
Selective reporting (reporting bias) Low risk All outcomes stated in ’Methods’ section
reported in ’Results’
Other bias Low risk No significant differences in the baseline
characteristics of the study participants
Ataga 2011
Methods Phase III randomized, double-blind, placebo-controlled, parallel group study. There was
a screening phase, a 52-week treatment phase, and a follow-up evaluation 8 weeks after
the end of the study
Participants 297 participants were recruited from 75 centers in the USA, Jamaica, Brazil, France,
Trinidad and the UK. Participants aged between 16 and 65 years and had at least 2
episodes of painful crisis within the preceding 12 months that required medical attention
were included. Participants on hydroxyurea in preceding 12 months were required to be
on a stable dose of the drug prior to inclusion in the study
Interventions Participants were randomized to receive (in a 1:1 fashion):
1. senicapoc (loading dose of 20 mg twice daily for 4 days followed by 10 mg daily); or
2. placebo
Outcomes The primary end point was the frequency of sickle cell pain crises. TIme to the first
second and third acute painful crises was a secondary end point of the study (Ataga 2011)
. The effect of the drug on markers of hemolysis, hemoglobin, hematocrit, reticulocyte
count, red blood cell count and dense erythrocytes was also measured. Quality of life
measures were also included
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralized randomization protocol using
an integrated voice response system
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding (performance bias and detection
bias)
Participants
Low risk The participants were blinded.
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Ataga 2011 (Continued)
Blinding (performance bias and detection
bias)
Clinicians
Low risk The treating physicians were blinded.
Blinding (performance bias and detection
bias)
Outcome assessors
Low risk The review committee was blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Modified intent to treat population was
used for analysis. The study had to be ter-
minated prematurely because it was un-
likely to meet the primary end point
Selective reporting (reporting bias) Low risk All outcomes stated in ’Methods’ section
reported in ’Results’
Other bias Low risk No significant differences in the baseline
characteristics of the study participants
Gupta 1995
Methods Double-blind, placebo-controlled, randomized controlled trial
Participants 145 participants from India with SS disease, aged over 5 years. 15 participants were lost
to follow up
Interventions Zinc (oral 220mg tds) or placebo (identical in appearance). Participantswere seenweekly,
follow up was for 1.5 years and the data were analysed at the end of the follow-up period
Outcomes Sickle related crises: vaso-occlusive; mixed; hemolytic; sequestration; and aplastic. Days
in hospital and working days lost
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk New Castle software was used to generate
randomization.
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding (performance bias and detection
bias)
Participants
Low risk The participants were blinded.
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Gupta 1995 (Continued)
Blinding (performance bias and detection
bias)
Clinicians
Low risk The treating physicians were blinded.
Blinding (performance bias and detection
bias)
Outcome assessors
Unclear risk Not discussed.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Fifteen, of the 145 participants recruited,
dropped out or were lost to follow up, and
these are not accounted for in the study
publication
Selective reporting (reporting bias) Low risk All outcomes stated in ’Methods’ section
reported in ’Results’
Other bias Unclear risk Little information was given regarding
baseline characteristics, including disease
severity andmedical history of participants,
making it difficult to ascertain if the groups
were sufficiently similar at the start of the
study
IV: intravenous
SCD: sickle cell disease
SS: sickle cell anemia
tds: three times daily
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adadevoh 1973 RCTofmegestrol acetate. There is no good recent evidence to suggest that sex hormones prevent dehydration
of the sickle red blood cells
Adams-Graves 1997 Trial of poloxamer 188 - inappropriate mechanism of action for inclusion in this review
Akinsulie 2005 RCT of Cajanus cajan. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the red blood cell membrane
Al-Jam’a 1999 Trial of isoxsurpine in treatment of sickle cell crises - rather than prevention
Alvim 2005 RCT of piracetam. There is a lack of evidence that the anti-sickling effect of the drug is due to a reduction
in water loss through the cell membrane
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(Continued)
Ataga 2002 Pharmacokinetic study of ICA 17043, with no measure of clinical outcomes of interest
Ayra 1996 RCT of tucaresol. Prevents sickling by shifting the oxygen affinity, not through red blood cell dehydration
Bartolucci 2009 RCT of ketoprofen for treatment of, rather than prevention of, vaso-occlusive crises. Not a study of a drug
involved in the prevention of red blood cell dehydration
Beatty 2007 Not a study of a drug involved in the prevention of red blood cell dehydration and vaso-occlusive crisis
Benjamin 1986 RCT of cetiedil citrate. Used in treatment rather than prevention of crises
Billet 1989 RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the red blood cell membrane
Cabannes 1983 RCT of cetiedil citrate. Used in treatment rather than prevention of crises
Cabannes 1984 RCT of ticlopidine. Mainly an inhibitor of platelet action, rather than anti-dehydration
De Abood 1997 RCT of Depo-Provera and Microgynon. There is no good evidence to suggest that sex hormones prevent
dehydration of the sickle red blood cells
De Ceulaer 1982 RCT of medroxyprogesterone acetate. There is no good recent evidence to suggest that sex hormones prevent
dehydration of the sickle blood red blood cells
De Ceulaer 1990 RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the red blood cell membrane
Gail 1982 RCT of urea. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the
sickle red blood cells
Gladwin 2011 Not a study of a drug involved in the prevention of red blood cell dehydration
Godeau 2003 RCT of ketoprofen for treatment, rather than prevention, of vaso-occlusive crises
Isaacs 1971 RCT of steroids. There is no good recent evidence to suggest that sex hormones prevent dehydration of the
sickle red blood cells
Jacobson 1997 Risk analysis using data from a previous RCT, in which morphine was administered in treatment, rather
than prevention, of acute chest syndrome
Lonsdorfer 1984 RCT of ticlopidine. Mainly an inhibitor of platelet action, rather than anti-dehydration
Mahmood 1969 RCT of a phenothiazine. Used in treatment rather than prevention of crises
Manion 2001 Pharmacokinetic study of aspartame, with no measure of outcomes of interest
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(Continued)
Manrique 1987 RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the red blood cell membrane
Orringer 1991 RCT of 12C79, which prevents sickling primarily by increasing oxygen affinity, with possible secondary
effects on the potassium-chloride co-transport channels in the red blood cell membrane
Osamo 1981 Trial of aspirin. There is no evidence that any anti-sickling action is due to a reduction in dehydration of
the sickle red blood cells
Oski 1968 Study not randomized, looks at promazine chloride.
Oyewo 1987 Study of diflusinal, anti-sickling effects not due to red blood cell dehydration
Pace 2003 Phase II RCT of N-Acetylcysteine for prevention of sickle cell related vaso-occlusion and formation of dense
cells. There is insufficient evidence that N-Acetylcysteine acts via red blood cell dehydration to include this
study in the review
Pichard 1987 RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the cell membrane
Piracetam Study 1998 RCT of piracetam. There is a lack of evidence that the anti-sickling effect of the drug is due to a reduction
in water loss through the cell membrane
Poflee 1991 RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the cell membrane
Qari 2007 RCT of tinzaparin. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the red blood cell membrane
Rubio 1992 Pharmacokinetic study of diltiazem, with no measure of outcomes of interest
Semple 1984 RCT of ticlopidine. Mainly an inhibitor of platelet action, rather than anti-dehydration
Silva-Pinto 2007 Study of hydroxyurea, no measure of clinical outcomes of interest
Teuscher 1988 RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the cell membrane
Toppet 2000 Non-randomized ex-vivo study of sodium cromoglicate, an anti-sickling agent, majority of patients also
taking hydroxyurea
Urea Trial 1974 RCT of urea. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the
sickle red blood cells
Urea Trial 2 1974 RCT of urea. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the
sickle red blood cells
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(Continued)
Urea Trial 3 1974 RCT of urea. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the
sickle red blood cells
Uzun 2010 Study of tramadol or meperidine for treatment of, rather than prevention of, vaso-occlusive crises. Not a
study of a drug involved in the prevention if red blood cell dehydration
Wallen 2007 Not a study of a drug involved in the prevention of red blood cell dehydration
Wambebe 2001 RCT of Niprisan, a naturally occurring compound. There is no evidence that any anti-sickling action is due
to a reduction in dehydration of red blood cells
Weiner 2002 Study of nitric oxide. There is no evidence that the anti-sickling effect of the drug is due to a reduction in
water loss through the red blood cell membrane
Wynn 2007 Study of hydroxyurea, no measure of clinical outcomes of interest
Zago 1984 Trial of aspirin. There is no evidence that any anti-sickling action is due to a reduction in dehydration of
the sickle red blood cells
RCT: randomized controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Anti-sickling drug versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Number of other serious
sickle-related complications
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Overall 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Quality of life measures 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Hospital stay per crisis
(days)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Loss of work days/crisis 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Anti-sickling drug versus placebo, Outcome 1 Mortality.
Review: Drugs for preventing red blood cell dehydration in people with sickle cell disease
Comparison: 1 Anti-sickling drug versus placebo
Outcome: 1 Mortality
Study or subgroup Anti-sickling drug Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gupta 1995 0/65 0/65 Not estimable
0.1 0.2 0.5 1 2 5 10
Favours drug tmt Favours placebo
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Analysis 1.2. Comparison 1 Anti-sickling drug versus placebo, Outcome 2 Number of other serious sickle-
related complications.
Review: Drugs for preventing red blood cell dehydration in people with sickle cell disease
Comparison: 1 Anti-sickling drug versus placebo
Outcome: 2 Number of other serious sickle-related complications
Study or subgroup Anti-sickling drug Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Overall
Gupta 1995 65 2.46 (1.04) 65 5.29 (2.58) -2.83 [ -3.51, -2.15 ]
-4 -2 0 2 4
Favours drug tmt Favours placebo
Analysis 1.3. Comparison 1 Anti-sickling drug versus placebo, Outcome 3 Quality of life measures.
Review: Drugs for preventing red blood cell dehydration in people with sickle cell disease
Comparison: 1 Anti-sickling drug versus placebo
Outcome: 3 Quality of life measures
Study or subgroup Anti-sickling drug Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Hospital stay per crisis (days)
Gupta 1995 65 4.3 (2.2) 65 3.9 (1.6) 0.40 [ -0.26, 1.06 ]
2 Loss of work days/crisis
Gupta 1995 65 3.4 (2.18) 65 4.9 (2.1) -1.50 [ -2.24, -0.76 ]
-4 -2 0 2 4
Favours drug tmt Favours placebo
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A P P E N D I C E S
Appendix 1. Search of trial registries
Trial registry Terms Date of search
WHO ICTRP “sickle cell dehydration” and “sickle cell red cell dehy-
dration”
01 July 2018
ClinicalTrials.gov “sickle cell dehydration” and “sickle cell red cell dehy-
dration”
01 July 2018
WH A T ’ S N E W
Last assessed as up-to-date: 18 October 2018.
Date Event Description
18 October 2018 New search has been performed A search of the Cochrane Cystic Fibrosis and Genetic
DisordersGroup’sHaemoglobinopathiesTrialsRegister
identified 135 potentially eligible references, none of
which were eligible for any section of the review
18 October 2018 New citation required but conclusions have not
changed
A new summary of findings table has been included
in the review (Summary of findings for the main
comparison). All relevant sections of the review have
therefore been updated to incorporate the contents of
this new table
Given this is no longer an active area of research, this
review will no longer be regularly updated
H I S T O R Y
Protocol first published: Issue 1, 2002
Review first published: Issue 4, 2002
Date Event Description
4 March 2016 New citation required but conclusions have not
changed
We havemade onlyminor changes to the text through-
out the review for this 2016 update
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(Continued)
4 March 2016 New search has been performed We searched theCochrane Cystic Fibrosis andGenetic
Disorders Group’s Haemoglobinopathies Trials Regis-
ter and 28 references were identified; however, none
were eligible for inclusion in any section of the review
We will continue to run searches to identify any po-
tentially relevant trials; however, we do not plan to up-
date other sections of the review until new trials are
published
19 April 2012 New search has been performed A search of the Group’s Haemoglobinopathies Trials
Register identified 34 references of which one has been
listed as an included study (Ataga 2011) and three
as excluded studies (Bartolucci 2009; Gladwin 2011;
Uzun 2010).
19 April 2012 New citation required but conclusions have not
changed
A new study has been included in the review but did
not lead to a change in conclusions (Ataga 2011).
20 September 2010 Amended Contact details updated.
11 November 2009 New search has been performed A search of the Group’s Trials Register identified eight
new references which were potentially eligible for in-
clusion in this review
One new study was included in the review (Ataga
2008).
Seven of these have been excluded; four references
were additional references to already excluded studies
(Beatty 2007; Qari 2007; Weiner 2002; Wynn 2007)
; and three were references to new studies (Akinsulie
2005; Silva-Pinto 2007; Wallen 2007).
Through personal communication,we have details of a
Phase III trial for which publication is pending (Ballas
2009). Full details will be included in a future update
11 November 2009 New citation required but conclusions have not
changed
A new lead author (SN) has updated this review with
the existing co-author (SB)
4 September 2008 Amended Converted to new review format.
19 July 2007 New citation required and conclusions have changed Substantive amendment.
A new review team has updated this review. Dr Priya
C. Singh is now lead author with Dr Samir K. Ballas
as co-author.
The former lead author, Ceri Hirst (née Riddington)
, and former co-author Dr Lucia de Franceschi are no
longer active authors on the review.
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One trial previously included in this review has been
removed (Piracetam Study 1998). The piracetam trial
was excluded since the current authors believe there is
insufficient evidence that it acts primarily via the red
cell membrane to improve red cell rheology.
The search of theGroup’sHaemoglobinopathies Trials
Register in November 2006 identified trials possibly
eligible for inclusion. Two references were to already
excluded studies and these references have been added
to the appropriate study IDs (Adams-Graves 1997;
Orringer 1991). One reference has been added to
Excluded studies (Alvim 2005).
1 June 2004 New search has been performed The search of the Group’s trials register identified eight
new references, however, none were found to be eligi-
ble for inclusion in the review
Five references to three newly identified studies have
been excluded. Details of these studies can be found
in the Excluded studies section of the review (Adams-
Graves 1997; Al-Jam’a 1999; Godeau 2003; Jacobson
1997; Pace 2003).
Three references identified were to two already ex-
cluded studies (Ataga 2002; Wambebe 2001). These
additional references have been added to the appropri-
ate study IDs
1 July 2003 New search has been performed Five new studies have been identified for inclusion
within the Excluded studies section of this review.
C O N T R I B U T I O N S O F A U T H O R S
Review from Issue 4, 2009
Dr Singh has stepped down from the review team and Dr Nagalla is now the lead author for this review. Together with Dr Ballas, Dr
Nagalla has updated this review and acts as guarantor for this and subsequent versions of the review.
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Review from Issue 4, 2007
Dr Singh is now lead author and updated the review with Dr Samir Ballas (co-author). Dr Singh acts as guarantor of the review. Dr
Singh reviewed the current literature on piracetam and revised the manuscript with advice from Dr Ballas.
Drs Hirst and de Franceschi have stepped down as active authors on this review.
Review up to Issue 3, 2007
The review was conceived by the Cochrane Cystic Fibrosis and Genetic Disorders Group and designed by Dr Hirst (née Riddington).
Dr Hirst and the Cochrane Cystic Fibrosis and Genetic Disorders Group conducted searches for relevant studies.
Dr Hirst and Dr de Franceschi screened, appraised and abstracted data for the review. Additional information from authors was sought
by Dr Hirst were necessary.
Data entry was performed byDrHirst and interpreted byDrHirst with advice from the Cochrane Cystic Fibrosis and Genetic Disorders
Group.
D E C L A R A T I O N S O F I N T E R E S T
Both authors: none known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the
Cochrane Cystic Fibrosis and Genetic Disorders Group.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acetamides [∗therapeutic use]; Anemia, Sickle Cell [∗blood]; Antisickling Agents [∗therapeutic use]; Clinical Trials, Phase II as Topic;
Clinical Trials, Phase III as Topic; Dehydration [∗prevention & control]; Early Termination of Clinical Trials; Erythrocyte Aging
[drug effects]; Erythrocytes [∗drug effects]; Piracetam [therapeutic use]; Randomized Controlled Trials as Topic; Trityl Compounds
[∗therapeutic use]; Zinc Sulfate [∗therapeutic use]
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MeSH check words
Humans
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